Pharmaceutical

First targeted alpha therapy wins FDA breakthrough device designation

RadioMedix and Orano Med’s radioligand therapy AlphaMedix (lead-212-Dotamtate) is currently in a Phase II trial.

Feb 12, 2024 - 18:00
First targeted alpha therapy wins FDA breakthrough device designation
RadioMedix and Orano Med’s radioligand therapy AlphaMedix (lead-212-Dotamtate) is currently in a Phase II trial.
Read the original article

Tags:

Previous Article

Disc wins orphan drug tag for rare blood cancer  

Next Article

CSL’s ‘big’ post-heart attack drug fails in Phase III trial

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

CureVac gets an early date in Covid-19 vaccine patent case with Pfizer/BioNTech

CureVac gets an early date in Covid-19 vaccine patent c...

May 22, 2023

UKHSA signs influenza vaccine deal with CSL Seqirus

UKHSA signs influenza vaccine deal with CSL Seqirus

Sep 27, 2023

Elahere secures full approval from FDA for types of ovarian cancer

Elahere secures full approval from FDA for types of ova...

Mar 26, 2024